牛牛AI助理已提取核心訊息
Morgan Stanley has filed an amended Schedule 13G with the United States Securities and Exchange Commission on March 7, 2024, indicating a change in their holdings of Novavax Inc. common stock. As of February 29, 2024, Morgan Stanley reported shared voting power over 2,427,012 shares and shared dispositive power over 2,454,328 shares of Novavax, representing 1.8% of the company's class of securities. This filing signifies that Morgan Stanley no longer holds more than five percent of Novavax's securities, as they have ceased to be the beneficial owner of more than five percent of the class of securities. The filing was made in accordance with Rule 13d-1(b) under the Securities Exchange Act of 1934, and Morgan Stanley has certified that the securities were acquired and are held in the ordinary course of business, not with the purpose of changing or influencing the control of Novavax.
Morgan Stanley has filed an amended Schedule 13G with the United States Securities and Exchange Commission on March 7, 2024, indicating a change in their holdings of Novavax Inc. common stock. As of February 29, 2024, Morgan Stanley reported shared voting power over 2,427,012 shares and shared dispositive power over 2,454,328 shares of Novavax, representing 1.8% of the company's class of securities. This filing signifies that Morgan Stanley no longer holds more than five percent of Novavax's securities, as they have ceased to be the beneficial owner of more than five percent of the class of securities. The filing was made in accordance with Rule 13d-1(b) under the Securities Exchange Act of 1934, and Morgan Stanley has certified that the securities were acquired and are held in the ordinary course of business, not with the purpose of changing or influencing the control of Novavax.
摩根士丹利已於2024年3月7日向美國證券交易委員會提交了經修訂的附表13G，表明其持有的Novavax Inc.普通股發生了變化。截至2024年2月29日，摩根士丹利報告了對2427,012股股票的共同投票權，對2,454,328股Novavax股票共享處置權，佔該公司證券類別的1.8％。該文件表明，摩根士丹利不再持有超過5％的Novavax證券，因爲他們已不再是該類別超過5％的證券的受益所有人。該文件是根據1934年《證券交易法》第13d-1（b）條提交的，摩根士丹利已證明這些證券是在正常業務過程中收購和持有的，其目的不是改變或影響Novavax的控制權。
摩根士丹利已於2024年3月7日向美國證券交易委員會提交了經修訂的附表13G，表明其持有的Novavax Inc.普通股發生了變化。截至2024年2月29日，摩根士丹利報告了對2427,012股股票的共同投票權，對2,454,328股Novavax股票共享處置權，佔該公司證券類別的1.8％。該文件表明，摩根士丹利不再持有超過5％的Novavax證券，因爲他們已不再是該類別超過5％的證券的受益所有人。該文件是根據1934年《證券交易法》第13d-1（b）條提交的，摩根士丹利已證明這些證券是在正常業務過程中收購和持有的，其目的不是改變或影響Novavax的控制權。
有用
沒用